Akebia Therapeutics (AKBA) PT Raised to $18 at Needham & Company
Needham & Company analyst Chad Messer raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $18.00 (from $15.00) while maintaining a Buy rating.
Needham & Company analyst Chad Messer raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $18.00 (from $15.00) while maintaining a Buy rating.